Aktis Oncology completed a $318 million initial public offering and will trade on Nasdaq under ticker AKTS. The Boston-based radiopharmaceutical developer priced 17.65 million shares at $18 each and disclosed that Eli Lilly purchased $100 million of the offering. Aktis is advancing two radioconjugates—AKY-1189 (Nectin‑4) and AKY-2519 (B7‑H3)—with Phase 1 readouts expected in 2027 and earlier private funding of roughly $346 million behind the programs. The IPO marks the first biotech public offering of 2026 and signals renewed investor appetite for radiopharmaceutical platforms after recent commercial successes in the space. Radiopharma companies have attracted partnerships with big pharma—Lilly, BMS and Novartis among them—helping validate the modality and driving capital into specialized oncology plays. Note: radiopharmaceuticals are drugs that deliver radioisotopes to tumors for targeted imaging or radiation-based therapy.